Critical Review: BioNxt Solutions (OTCMKTS:BNXTF) vs. Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ:CPRX) and BioNxt Solutions (OTCMKTS:BNXTF) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Institutional and Insider Ownership

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Catalyst Pharmaceuticals and BioNxt Solutions”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96 million	6.46	$214.33 million	$1.74	18.10
BioNxt Solutions	$20,000.00	1,462.97	-$5.03 million	($0.05)	-4.30

Catalyst Pharmaceuticals has higher revenue and earnings than BioNxt Solutions. BioNxt Solutions is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Catalyst Pharmaceuticals and BioNxt Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
BioNxt Solutions	N/A	N/A	-1,173.20%

Analyst Ratings

This is a breakdown of current recommendations for Catalyst Pharmaceuticals and BioNxt Solutions, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0	6	1	2	2.56
BioNxt Solutions	0	0	0	0	0.00

Catalyst Pharmaceuticals presently has a consensus target price of $32.00, indicating a potential upside of 1.62%. Given Catalyst Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Catalyst Pharmaceuticals is more favorable than BioNxt Solutions.

Risk & Volatility

Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, BioNxt Solutions has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Summary

Catalyst Pharmaceuticals beats BioNxt Solutions on 14 of the 15 factors compared between the two stocks.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

About BioNxt Solutions

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.